InterVenn Biosciences, a startup founded and headed by Aldo Carrascoso, a Filipino native based in South San Francisco, California, with offices in Australia and Malaysia aside from the Philippines, is pioneering a new AI-powered approach to predict, prevent, and observe disease progression. InterVenn has raised a total of US$278.1 million in funding over five rounds. InterVenn has developed a powerful AI-enabled software platform that can perform glycoproteomic analysis and can work on a variety of mass spectrometry instruments to create high-throughput, automated analysis solutions for both research and clinical applications. The platform identifies patient-specific cancer biomarkers and uses those to develop liquid biopsy tests that can detect cancer and determine how well each patient will respond to available treatments.

InterVenn is currently working on the development and commercialization of Dawn™, assessing whether a patient is likely to benefit from immuno-oncology therapies. The startup has also developed GLORI™ - a laboratory-developed test for ovarian cancer diagnosis which recently completed clinical and analytical validation based on a multinational trial, VOCAL, carried out in South East Asia, including the Philippine General Hospital, National Kidney and Transplant Institute, and The Medical City in the Philippines, in the US, and Australia. (BOI)